Upregulation of ERK1/2-eNOS via AT2 receptors decreases the contractile response to angiotensin II in resistance mesenteric arteries from obese rats

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Hagihara, Graziela N ^a   Lobato, Nubia S ^b   Filgueira, Fernando P ^b   Akamine, Eliana H ^a   Aragão, Danielle S ^c   Casarini, Dulce E ^c   Carvalho, Maria Helena C ^a   Fortes, Zuleica B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTAMATE SODIUM; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; 1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 3; N(G) NITROARGININE METHYL ESTER; PYRIDINE DERIVATIVE; VASOCONSTRICTOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY DILATATION; ARTERY RESISTANCE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERINSULINEMIA; MALE; MESENTERIC ARTERY; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RECEPTOR BLOCKING; VASOCONSTRICTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IN VITRO STUDY; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; UPREGULATION; VASCULAR ENDOTHELIUM; WISTAR RAT;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; BLOTTING, WESTERN; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; IMIDAZOLES; IN VITRO TECHNIQUES; MALE; MESENTERIC ARTERIES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OBESITY; PHOSPHORYLATION; PYRIDINES; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 2; UP-REGULATION; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 84929597509     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106029     Document Type: Article

References (50)

1. Chiu AT, Herblin WF, McCall DE, Ardecky RJ, Carini DJ, et al. (1989) Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun 165: 196-203. (Pubitemid 20012475)
2. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, et al. (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 25: 205-251. (Pubitemid 23191415)
3. Chung O, Csikos T, Unger T. (1999) Angiotensin II receptor pharmacology and AT1-receptor blockers. J Hum Hypertension Suppl1: S11-20. (Pubitemid 29057650)
4. Zhao Y, Liu J, Li L, Liu L, Wu L (2005) Role of Ras/PKCzeta/MEK/ERK1/2 signaling pathway in angiotensin II-induced vascular smooth muscle cell proliferation. Regul Pept 128: 43-50. (Pubitemid 40255533)
5. Touyz RM, Yao G, Viel E, Amiri F, Schiffrin EL (2004) Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens 22: 1141-1149. (Pubitemid 38721006)
6. Touyz RM, Deng LY, He G, Wu XH, Schiffrin EL (1999) Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries: role of extracellular signal-regulated kinases. J Hypertens 17: 907-916. (Pubitemid 29322178)
7. Ushio-Fukai M, Alexander RW, Akers M, Griendling KK (1998) p38 Mitogen activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem 273: 15022-15029. (Pubitemid 28272796)
8. Touyz RM, He G, Wu XH, Park JB, Mabrouk ME, et al. (2001) Src is an important mediator of extracellular signal-regulated kinase 1/2- dependent growth signaling by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients. Hypertension 38: 56-64. (Pubitemid 34224771)
9. Ishida M, Ishida T, Thomas SM, Berk BC (1998) Activation of extracellular signal-regulated kinases (ERK1/2) by angiotensin II is dependent on c-Src in vascular smooth muscle cells. Circ Res 82: 7-12. (Pubitemid 28074013)
10. Carey RM, Siragy HM (2003) Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 24: 261-271. (Pubitemid 36733542)
11. Carey RM (2005) Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 45: 840-844.
12. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, et al. (2004) Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 109: 2296-2301. (Pubitemid 38656868)
13. Akishita M, Yamada H, Dzau VJ, Horiuchi M (1999) Increased vasoconstrictor response of the mouse lacking angiotensin II type 2 receptor. Biochem Biophys Res Commun 261: 345-349. (Pubitemid 29392479)
14. Lee JH, Xia S, Ragolia L (2008) Upregulation of AT2 receptor and iNOS impairs angiotensin II-induced contraction without endothelium influence in young normotensive diabetic rats. Am J Physiol Regul Integr Comp Physiol 295: 144-154.
15. Akishita M, Horiuchi M, Yamada H, Zhang L, Shirakachi G, et al. (2000) Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol. Genomics 2: 13-20.
16. Engeli S, Sharma AM (2000) The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med 79: 21-29.
17. Siddiqui AH, Hussain T (2007) Enhanced AT1 receptor-mediated vasocontractile response to ANG II in endothelium-denuded aorta of obese Zucker rats. Am J Physiol Heart Circ Physiol 292: 1722-1727.
18. Stepp DW, Boesen EI, Sullivan JC, Mintz JD, Hair CD, et al. (2007) Obesity augments vasoconstrictor reactivity to angiotensin II in the renal circulation of the Zucker rat. Am J Physiol Heart Circ Physiol 293: 2537-2542.
19. Bost F, Aouadi M, Caron L, Even P, Belmonte N, et al. (2005) The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis. Diabetes 54: 402-411.
20. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, et al. (2002) A central role for JNK in obesity and insulin resistance. Nature 420: 333-336. (Pubitemid 35398190)
21. Sugden PH, Clerk A (1997) Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. Cell Signal 9: 337-351. (Pubitemid 27367575)
22. Taniyama Y, Ushio-Fukai M, Hitomi H, Rocic P, Kingsley MJ, et al. (2004) Role of p38 MAPK and MAPKAPK-2 in angiotensin II-induced Akt activation in vascular smooth muscle cells. Am J Physiol Cell Physiol 287: 494-499.
23. Lobato NS, Filgueira FP, Akamine EH, Davel AP, Rossoni LV, et al. (2011) Obesity induced by neonatal treatment with monosodium glutamate impairs microvascular reactivity in adult rats: role of NO and prostanoids. Nutr Metab Cardiovasc Dis 21: 808-816.
24. Matthew DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and b-cell function form fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419. (Pubitemid 15018832)
25. Franco MC, Casarini DE, Carneiro-Ramos MS, Sawaya AL, Barreto-Chaves ML, et al. (2008) Circulating renin-angiotensin system and catecholamines in childhood: is there a role for birthweight? Clin Sci 114: 375-380. (Pubitemid 351397386)
26. Santos RA, Krieger EM, Greene LJ (1985) An improved fluorometric assay of rat serum and plasma converting enzyme. Hypertension 7: 244-252. (Pubitemid 15093650)
27. Naffah-Mazzacoratti MG, Casarini DE, Fernandes MJS, Cavalheiro EA (1992) Serum catecholamine levels determined by high performance liquid chromatography coupled with electrochemical detection. Arq Bras Endocrinol Metab 36: 119-122.
28. Mulvany MJ, Halpern W (1977) Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41: 19-26. (Pubitemid 8132079)
29. Jull B, Aalkjaer C, Mulvany MJ (1987) Responses of femoral resistance vessels to angiotensin in vitro. Eur J Pharmacol 135: 61-68. (Pubitemid 17051010)
30. Barton M, Carmona R, Morawietz H, d'Uscio LV, Goettsch W, et al. (2000) Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension 35: 329-336. (Pubitemid 30054195)
31. Rahmouni K, Mark AL, Haynes WG, Sigmund CD (2004) Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity. Am J Physiol Endocrinol Metab 286: 891-895.
32. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M (1981) The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 304: 930-933. (Pubitemid 11101080)
33. Santos RA, Ferreira AJ (2007) Angiotensin-(1-7) and the rennin angiotensin system. Curr Opin Nephrol Hypertens 16: 122-128.
34. Ferreira AJ, Santos RAS, Bradford CN, Mecca A, Sumners C, et al. (2010) Therapeutic Implications of the Vasoprotective Axis of the RAS in Cardiovascular Diseases. Hypertension 55: 207-213.
35. Santos SH, Fernandes LR, Pereira CS, Guimarães AL, de Paula AM, et al. (2012) Increased circulating angiotensin-(1-7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet. Regul Pept 178: 64-70.
36. Bilman V, Mares-Guia L, Nadu AP, Bader M, Campagnole-Santos MJ, et al. (2012) Decreased hepatic gluconeogenesis in transgenic rats with increased circulating angiotensin-(1-7). Peptides 37: 247-251.
37. Santos SH, Simões E, Silva AC (2013) The Therapeutic Role of Renin-Angiotensin System Blockers in Obesity- Related Renal Disorders. Curr Clin Pharmacol 9: 2-9.
38. Lassegue B, Alexander RW, Nickenig G, Clark M, Murphy TJ, et al. (1995) Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation. Mol Pharmacol 48: 601-609.
39. Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292: 82-97.
40. Hakam AC, Hussain T (2005) Renal angiotensin II type-2 receptors are upregulated and mediate the candesartan-induced natriuresis/diuresis in obese Zucker rats. Hypertension 45: 270-275. (Pubitemid 40179971)
41. Touyz RM, Endemann D, He G, Li JS, Schiffrin EL (1999) Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR. Hypertension 33: 366-372. (Pubitemid 29065686)
42. Barber MN, Sampey DB, Widdop RE (1999) AT2 receptor stimulation enhances antihypertensive effect of AT1 receptor antagonist in hypertensive rats. Hypertension 34: 1112-1116.
43. Siragy HM, Carey RM (1997) The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 100: 264-269. (Pubitemid 27349072)
44. Hiyoshi H, Yayama K, Takano M, Okamoto H (2005) Angiotensin type 2 receptor-mediated phosphorylation of eNOS in the aortas of mice with 2-kidney, 1-clip hypertension. Hypertension 45: 967-973. (Pubitemid 40628945)
45. Touyz RM, He G, Deng LY, Schiffrin EL (1999) Role of extracellular signal-regulated kinases in angiotensin II-stimulated contraction of smooth muscle cells from human resistance arteries. Circulation 99: 392-399. (Pubitemid 29051265)
46. Ishida M, Ishida T, Thomas SM, Berk BC (1998) Activation of extracellular signal-regulated kinases (ERK1/2) by angiotensin II is dependent on c-Src in vascular smooth muscle cells. Circ Res 82: 7-12. (Pubitemid 28074013)
47. Ishida T, Ishida M, Suero J, Takahashi M, Berk BC (1999) Agonist-stimulated cytoskeletal reorganization and signal transduction at focal adhesions in vascular smooth muscle cells require c-Src. J Clin Invest 103: 789-797. (Pubitemid 29152624)
48. Meloche S, Landry J, Huot J, Houle F, Marceau F, et al. (2000) p38 MAP kinase pathway regulates angiotensin II-induced contraction of rat vascular smooth muscle. Am. J. Physiol Heart Circ Physiol 279: 741-751.
49. Zhou MS, Schulman IH, Chadipiralla K, Raij L (2010) Role of c-Jun N-terminal kinase in the regulation of vascular tone. J Cardiovasc Pharmacol Ther 15: 78-83.
50. Garrido AM, Griendling KK (2009) NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol 302: 148-158. Tecnológico